ArticleCureus2022
Hemophagocytic Lymphohistiocytosis in the Setting of Disseminated Histoplasmosis and Uncontrolled HIV.
Article in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Hemophagocytic Lymphohistiocytosis in HIV/AIDS: Who Fired the First Shot, the Virus or Its Companions?Cureus · 2025Article
- Pathophysiology and clinical outcomes of pancytopenia in disseminated histoplasmosis: a scoping review.Infection · 2025Article
- Clinical and Biochemical Characteristics of Hemophagocytic Lymphohistiocytosis in People Living With HIV and Disseminated Histoplasmosis at a Tertiary Hospital in Mexico.Open forum infectious diseases · 2024Article
- Macrophage Activation Syndrome in Viral Sepsis.Viruses · 2024Review
- Article
- Hemophagocytic Lymphohistiocytosis in a Patient with Hodgkin Lymphoma, HIV, and Epstein-Barr Virus.Cureus · 2023Article
- Hemophagocytic Lymphohistiocytosis Due to Disseminated Histoplasmosis in a Young Patient with AIDS.Journal of global infectious diseasesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hemophagocytic lymphohistiocytosis (HLH) is a rare and life-threateningly aggressive syndrome caused by excessive immune activation. It involves the abnormal activation of lymphocytes and macrophages which leads to tissue destruction and inflammation. Traditionally HLH classification is currently separated into primary and secondary HLH based on genetic versus nongenetic events such as infection, malignancy, or autoimmune disorders. In this case report, we present the case of a middle-aged woman presenting with HIV with medication noncompliance who presented to the emergency department with pancytopenia as well as disseminated histoplasmosis and was diagnosed with HLH based on the HLH-2004 guidelines and treated in accordance with the HLH-94 protocol. The patient also underwent treatment for the management of her histoplasmosis with a favorable outcome. This case demonstrates that HLH is best treated through management of the underlying process that triggered the syndrome such as infection as in this patient in addition to management per HLH-94 protocol early on in the course of the disease in order to have the best chance at a positive clinical outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.